MetLife director awarded 678 shares in stock plan

MetLife Inc. director Robert Glenn Hubbard acquired 678 shares of Common Stock as a compensation-related award.

Rhea-AI Filing Summary

MetLife Inc. director Robert Glenn Hubbard acquired 678 shares of Common Stock as a compensation-related award. The shares were credited on June 9, 2026 at $85.57 per share as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

After this transaction, Hubbard directly holds 106,557 MetLife common shares. The filing characterizes the event as a grant or award, not an open-market purchase.

Insider Trade Summary

Grant/Award: 678 shares

Grant/Award 1 txn

Insider HUBBARD ROBERT GLENN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	678	$85.57	$58K

Holdings After Transaction: Common Stock — 106,557 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Key Figures

Stock award size: 678 shares Imputed price per share: $85.57 per share Total holdings after transaction: 106,557 shares +1 more

4 metrics

Stock award size 678 shares Common Stock grant on June 9, 2026

Imputed price per share $85.57 per share Value used for dividend reinvestment on deferred shares

Total holdings after transaction 106,557 shares Direct MetLife common stock held by Hubbard after award

Transaction type Grant/award acquisition Form 4 code A, non-derivative Common Stock

Key Terms

Imputed reinvestment of dividends, Deferred shares, MetLife Deferred Compensation Plan for Non-Management Directors

3 terms

Imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan"

Deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

MetLife Deferred Compensation Plan for Non-Management Directors financial

"pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MET director Robert Glenn Hubbard report?

Robert Glenn Hubbard reported acquiring 678 MetLife common shares as a grant-related transaction. The shares resulted from dividend reinvestment on deferred shares under a non-management director deferred compensation plan, rather than from an open-market stock purchase.

At what price were Robert Glenn Hubbard’s new MET shares recorded?

The 678 MetLife shares were recorded at a price of $85.57 per share. This price reflects the value used for the imputed reinvestment of dividends on deferred shares within the MetLife Deferred Compensation Plan for Non-Management Directors.

How many MetLife (MET) shares does Robert Glenn Hubbard hold after this transaction?

After the award, Robert Glenn Hubbard directly holds 106,557 MetLife common shares. This total incorporates the 678 shares credited on June 9, 2026 through dividend reinvestment tied to his deferred compensation arrangements as a non-management director.

Was Robert Glenn Hubbard’s MET Form 4 transaction an open-market stock purchase?

The transaction was not an open-market stock purchase. It is described as a grant or award acquisition, arising from imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, rather than a discretionary market buy.

What is the MetLife Deferred Compensation Plan for Non-Management Directors mentioned in the filing?

The plan allows non-management directors to defer receipt of payable MetLife common shares. In this case, dividends on those deferred shares were reinvested, creating 678 additional common shares credited to Robert Glenn Hubbard, as disclosed in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUBBARD ROBERT GLENN

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A(1)		678	A	$85.57	106,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)